Novo Nordisk Statistics

Total Valuation

Novo Nordisk has a market cap or net worth of EUR 349.41 billion. The enterprise value is 347.01 billion.

Market Cap	349.41B
Enterprise Value	347.01B

Important Dates

The next estimated earnings date is Wednesday, February 5, 2025.

Earnings Date	Feb 5, 2025
Ex-Dividend Date	Aug 15, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.86%
Shares Change (QoQ)	-0.11%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	3.16B

Valuation Ratios

The trailing PE ratio is 27.51.

PE Ratio	27.51
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	39.46
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.26, with an EV/FCF ratio of 33.28.

EV / Earnings	27.32
EV / Sales	9.57
EV / EBITDA	19.26
EV / EBIT	20.62
EV / FCF	33.28

Financial Position

The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.47.

Current Ratio	0.94
Quick Ratio	0.74
Debt / Equity	0.47
Debt / EBITDA	0.42
Debt / FCF	0.73
Interest Coverage	825.54

Financial Efficiency

Return on equity (ROE) is 88.73% and return on invested capital (ROIC) is 52.81%.

Return on Equity (ROE)	88.73%
Return on Assets (ROA)	22.49%
Return on Capital (ROIC)	52.81%
Revenue Per Employee	504,795
Profits Per Employee	176,710
Employee Count	64,319
Asset Turnover	0.78
Inventory Turnover	1.23

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -12.34% in the last 52 weeks. The beta is 0.15, so Novo Nordisk's price volatility has been lower than the market average.

Beta (5Y)	0.15
52-Week Price Change	-12.34%
50-Day Moving Average	102.48
200-Day Moving Average	116.68
Relative Strength Index (RSI)	22.55
Average Volume (20 Days)	96,157

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Novo Nordisk had revenue of EUR 36.28 billion and earned 12.70 billion in profits. Earnings per share was 2.84.

Revenue	36.28B
Gross Profit	30.72B
Operating Income	16.83B
Pretax Income	15.99B
Net Income	12.70B
EBITDA	17.85B
EBIT	16.83B
Earnings Per Share (EPS)	2.84

Full Income Statement

Balance Sheet

The company has 10.04 billion in cash and 7.64 billion in debt, giving a net cash position of 2.40 billion.

Cash & Cash Equivalents	10.04B
Total Debt	7.64B
Net Cash	2.40B
Net Cash Per Share	n/a
Equity (Book Value)	16.16B
Book Value Per Share	3.63
Working Capital	-1.77B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 15.85 billion and capital expenditures -5.43 billion, giving a free cash flow of 10.43 billion.

Operating Cash Flow	15.85B
Capital Expenditures	-5.43B
Free Cash Flow	10.43B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 84.66%, with operating and profit margins of 46.37% and 35.01%.

Gross Margin	84.66%
Operating Margin	46.37%
Pretax Margin	44.07%
Profit Margin	35.01%
EBITDA Margin	49.19%
EBIT Margin	46.37%
FCF Margin	28.73%

Dividends & Yields

This stock pays an annual dividend of 1.33, which amounts to a dividend yield of 1.32%.

Dividend Per Share	1.33
Dividend Yield	1.32%
Dividend Growth (YoY)	39.79%
Years of Dividend Growth	4
Payout Ratio	46.60%
Buyback Yield	0.86%
Shareholder Yield	2.18%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

The last stock split was on September 13, 2023. It was a forward split with a ratio of 2.

Last Split Date	Sep 13, 2023
Split Type	Forward
Split Ratio	2

Scores

Novo Nordisk has an Altman Z-Score of 10.12.

Altman Z-Score	10.12
Piotroski F-Score	n/a